Literature DB >> 17118316

Lung and cardiac tissue doses in left breast cancer patients treated with single-source breast brachytherapy compared to external beam tangent fields.

Richard Garza1, Kevin Albuquerque, Anil Sethi.   

Abstract

PURPOSE: We performed a retrospective analysis of doses to normal critical structures in 26 women with left-sided breast tumors treated with a high-dose-rate single source brachytherapy (SSB) system, versus whole breast external beam tangent fields (EBTF) using a computer model. METHODS AND MATERIALS: Each patient's EBTF radiation plan consisted of ipsilateral tangent fields normalized to 46 Gy. A complementary SSB radiation plan was designed to deliver 34 Gy in 10 fractions at 1cm into tissue enclosing a sphere of diameter 4.6 cm at tumor bed, simulating our institution's experience with the MammoSite applicator. Critical structure volumes and doses analyzed included the volume of whole heart and left ventricle receiving >25 Gy, and left lung (LL) receiving 20 and 13 Gy for EBTF plans. For SSB we determined the linear quadratic 2-Gy-equivalent high-dose-rate doses of 23.4, 20, and 14 Gy to be equivalent to 25, 20, and 13 Gy, respectively. We then compared the two doses for each critical structure.
RESULTS: The percent of whole heart receiving >25 Gy equivalent using EBTF and SSB was 2% and 0% (mean dose 2.52 vs. 1.65 Gy), left ventricle receiving >25 Gy using EBTF and SSB was 3% and 0% (mean dose 3.78 vs. 2.68 Gy), LL receiving >20 Gy using EBTF and SSB was 11.5% and 0.5%, and LL receiving >13 Gy using EBTF and SSB was 12.6% and 1.85% (mean dose to LL was 6.06 Gy for EBTF vs. 2.25 Gy for SSB), respectively.
CONCLUSIONS: When compared to EBTF, breast brachytherapy with SSB is associated with a significant decrease in mean dose and percentage volume receiving a given dose for each organ.

Entities:  

Mesh:

Year:  2006        PMID: 17118316     DOI: 10.1016/j.brachy.2006.08.001

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  6 in total

1.  Accelerated partial breast irradiation using external beam radiotherapy-A feasibility study based on dosimetric analysis.

Authors:  Surega Anbumani; Siddanna R Palled; Girish S Prabhakar; N Arunai Nambiraj; Anchineyan Pichandi
Journal:  Rep Pract Oncol Radiother       Date:  2012-06-15

2.  Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis.

Authors:  William C Dooley; James C Wurzer; Mohamed Megahy; Gary Schreiber; Tapan Roy; Gary Proulx; Susan Laduzinsky; Steven Lane; James Dalzell; Kambiz Dowlatshahi; Dwelvin Simmons; John P Thropay; Harish Ahuja; Peter Beitsch; Randall W Holt; Charles A Lee
Journal:  Onco Targets Ther       Date:  2011-01-12       Impact factor: 4.147

3.  Measurement of mean cardiac dose for various breast irradiation techniques and corresponding risk of major cardiovascular event.

Authors:  Tomas Rodrigo Merino Lara; Emmanuelle Fleury; Shahram Mashouf; Joelle Helou; Claire McCann; Mark Ruschin; Anthony Kim; Nadiya Makhani; Ananth Ravi; Jean-Philippe Pignol
Journal:  Front Oncol       Date:  2014-10-22       Impact factor: 6.244

Review 4.  Treatment techniques to reduce cardiac irradiation for breast cancer patients treated with breast-conserving surgery and radiation therapy: a review.

Authors:  Robert E Beck; Leonard Kim; Ning J Yue; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-11-14       Impact factor: 6.244

5.  Dose correction in lung for HDR breast brachytherapy.

Authors:  Eric Slessinger; Eric Pepin; Qingya Zhao; Li Zhao; Indra Das
Journal:  J Contemp Brachytherapy       Date:  2012-06-30

6.  Dose volume histogram analysis of normal structures associated with accelerated partial breast irradiation delivered by high dose rate brachytherapy and comparison with whole breast external beam radiotherapy fields.

Authors:  Alexandra J Stewart; Desmond A O'Farrell; Robert A Cormack; Jorgen L Hansen; Atif J Khan; Subhakar Mutyala; Phillip M Devlin
Journal:  Radiat Oncol       Date:  2008-11-19       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.